Jade Biosciences, Inc. (JBIO)
$14.39+1.70%Close
SELLCRISIS · day 26
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $469M
- Beta
- 1.45
- P/E (TTM)
- -4.88
- Short % float
- 49.90%
- Days to cover
- 11.3
- SI change
- +10.3%
- 1W
- +1.91%
- 1M
- -24.82%
- vs SPY 1W
- +0.75%
- vs SPY 1M
- -27.81%
Industry peers
FMP comparable companies · ranked by market cap
- VERASELLVera Therapeutics, Inc.$2.1BCRISISQ 21$29.88+0.50%
- TRAXSELLFirst Tracks Biotherapeutics Inc$1.1BQ 81$31.85-0.50%
- MLTXSELLMoonLake Immunotherapeutics$910MCRISISQ -0$10.82+2.27%
- ACRSSELLAclaris Therapeutics, Inc.$535MCRISISQ 9$3.83+1.06%
- CTNMSELLContineum Therapeutics, Inc.$503MRECOVERYQ 7$13.38+1.52%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on JBIO?
- LOPJLB’s latest quantitative signal on Jade Biosciences, Inc. (JBIO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is JBIO in?
- Jade Biosciences, Inc. (JBIO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Jade Biosciences, Inc. (JBIO) do?
- Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. …